CN113476555A - 一种用于心脑血管疾病的药剂及其制备方法与用途 - Google Patents
一种用于心脑血管疾病的药剂及其制备方法与用途 Download PDFInfo
- Publication number
- CN113476555A CN113476555A CN202110955747.2A CN202110955747A CN113476555A CN 113476555 A CN113476555 A CN 113476555A CN 202110955747 A CN202110955747 A CN 202110955747A CN 113476555 A CN113476555 A CN 113476555A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- extract
- cerebrovascular diseases
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 35
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 33
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000000284 extract Substances 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 241000604742 Machilus thunbergii Species 0.000 claims abstract description 27
- 235000004267 Persea thunbergii Nutrition 0.000 claims abstract description 27
- 239000007921 spray Substances 0.000 claims abstract description 27
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- 241001092035 Photinia Species 0.000 claims abstract description 18
- 239000000341 volatile oil Substances 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241001633680 Polygonatum odoratum Species 0.000 claims abstract description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 206010004542 Bezoar Diseases 0.000 claims abstract description 10
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 10
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 238000000889 atomisation Methods 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- 229940105902 mint extract Drugs 0.000 claims abstract description 10
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004556 brain Anatomy 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000011187 glycerol Nutrition 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000271309 Aquilaria crassna Species 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010027727 Mitral valve incompetence Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 2
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000291333 Serissa japonica Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 210000003459 common hepatic duct Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- -1 i.e. Chemical compound 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
本发明公开了一种用于心脑血管疾病的药剂及其制备方法与用途，该药剂的原料包含：棋楠树提取物、棋楠树叶提取物、棋楠精油、牛黄、麝香、薄荷提取物、冰片、玉竹、川芎、琥珀、甘油。该原料优选地包含：棋楠树提取物70g，棋楠树叶提取物70g，棋楠精油25g，牛黄25g，麝香25g，薄荷提取物15g，冰片25g，玉竹50g，川芎50g，琥珀50g，甘油150g。本发明还提供了该药剂的用途，该药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。本发明还提供了该外用雾化喷剂的制备方法。本发明提供的药剂，具有组方合理、用量少、效果显著、无毒副作用、迅速起效等特点，可用于各类心脑血管疾病，或用于急救心脑突发性的情况。
Description
技术领域
本发明涉及一种药物组合物及其制备方法与用途，具体地，涉及一种用于心脑血管疾病的药剂及其制备方法与用途。
背景技术
随着经济社会的发展，人们的生活方式的改变，导致心血管的发病率逐年增加，心血管死亡占城乡居民走死亡原因的首位，而每年死于心血管疾病的人数中就有一半以上死于心肌梗死。近年来的流行病学调查表明，中国人心肌梗死的发病率大约在55/100000，世界人口的发病率大约在65/100000。总体而言，中国急性心肌梗死城市的发病率高于农村，男性的发病率高于女性。因为急性心肌梗死是一个高度危险甚至会猝死的疾病，所以大部分人发病之后都必须住院治疗，因此，我国每年用于治疗心肌梗死的费用也相当的高。在中国每年约有350万人死于心血管疾病，其中心肌梗死患病人数约250万。近年来其发病率在逐渐升高，急性心肌梗死原因是因为冠状动脉粥样硬化，造成一支或者多支血管官腔狭窄出现心肌供血不足，而此时侧支循环又未充分建立，再次基础上一旦血供急剧减少或者中断，就会使得心肌严重而持久的缺血缺氧达到20-30分钟以上，就可以发生急性心肌梗死，然而目前市场上还没有具备有效的急救和预防保健的功能的药物产品。
发明内容
本发明的目的是提供一种药物组合物及其制备方法与用途，能够解决现有问题，用于中风偏瘫等心脑血管疾病，有效减轻患者痛苦。
为了达到上述目的，本发明提供了一种用于心脑血管疾病的药剂，其中，该药剂的原料包含：棋楠树提取物、棋楠树叶提取物、棋楠精油、牛黄、麝香、薄荷提取物、冰片、玉竹、川芎、琥珀、甘油。
上述的用于心脑血管疾病的药剂，其中，所述的原料按重量份数计包含：棋楠树提取物60～80份，棋楠树叶提取物60～80份，棋楠精油20～30份，牛黄20～30份，麝香20～30份，薄荷提取物10～20份，冰片20～30份，玉竹40～60份，川芎40～60份，琥珀40～60份，甘油100～200份。
上述的用于心脑血管疾病的药剂，其中，所述的原料按重量计包含：棋楠树提取物70g，棋楠树叶提取物70g，棋楠精油25g，牛黄25g，麝香25g，薄荷提取物15g，冰片25g，玉竹50g，川芎50g，琥珀50g，甘油150g。
本发明还提供了上述的用于心脑血管疾病的药剂的用途，其中，所述的药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
本发明还提供了上述的外用雾化喷剂的制备方法，其中，所述的方法为：按比例称量各药物，将固体原料研磨破碎成粉末，然后加水浸泡萃取，浓缩提纯，再与液体原料混合均匀超声后，制得外用雾化喷剂。
上述的外用雾化喷剂的制备方法，其中，所述的研磨破碎的粒度范围为50～60目。
上述的外用雾化喷剂的制备方法，其中，所述的加水浸泡的时间为24小时或以上。
上述的外用雾化喷剂的制备方法，其中，所述的浓缩提纯前后液体的体积比为30：1。
本发明提供的用于心脑血管疾病的药剂及其制备方法与用途具有以下优点：
本发明是将各原料按比例混合后提纯成可雾化精油，用电子雾化器吸入，反复吸纳多次。具有养心破淤、补阳还生、破淤通窍、开神醒魂等功效。可以治疗预防缓解心悸心烦心慌、心动过速、心肌梗塞、心绞痛、心脑血管堵塞、二尖瓣反流三尖瓣反流或关闭不严等各类心脏疾病。并可以治疗预防缓解中风偏瘫、口眼歪斜、四肢麻木、脑血管堵塞、脑溢血、脑梗塞等各类脑部疾病，或用于急救心脑突发性病况。
具体实施方式
以下对本发明的具体实施方式作进一步地说明。
本发明提供的用于心脑血管疾病的药剂，该药剂的原料包含：棋楠树提取物、棋楠树叶提取物、棋楠精油、牛黄、麝香、薄荷提取物、冰片、玉竹、川芎、琥珀、甘油。
棋楠即奇楠，是沉香的中的一种，又叫伽南香，别名奇南香、琪喃等。伽喃香为瑞香科植物沉香或白木香含有沉香树脂的沉香木。具有理气，止痛，通窍的功效。治胸闷不舒，气滞疼痛，风痰闭塞。功胜沉香。
棋楠树提取物、棋楠树叶提取物、棋楠精油分别是采用棋楠的不同部分，如树枝、树皮、树叶等，通过不同的溶剂进行萃取而得的。
牛黄为牛科动物黄牛或水牛的胆囊、胆管或肝管中的结石，全年均产。功能主治为：清心，化痰，利胆，镇惊。治热病神昏、谵语，癫痫发狂，小儿惊风抽搐，牙疳，喉肿，口舌生疮，痈疽，疔毒。
麝香为鹿科动物麝的雄兽香腺囊中的分泌物。一般每年冬、春取香1次，也有每年3、4月和7、8月取香2次。功能为：开窍，辟秽，通络，散瘀。主治中风，痰厥，惊痫，中恶烦闷，心腹暴痛，症瘕癖积，跌打损伤，痈疽肿毒。
薄荷提取物的外观为棕色粉末，提取来源为唇形科植物蒲荷的地上部分。含挥发油，油中主要为I-薄荷醇、1-薄荷酮及薄荷酯类等。主治：宣散风热，清头目，透疹。用于风热感冒、风温初起、头痛、目赤、喉痹、口疮、风疹、麻疹、胸胁胀闷。
冰片又名片脑、桔片、艾片、龙脑香、梅花冰片、羯布罗香、梅花脑、冰片脑、梅冰等，是由菊科艾纳香茎叶或樟科植物龙脑樟枝叶经水蒸汽蒸馏并重结晶而得。无色透明或半透明的片状松脆结晶，气清香，味辛、凉；含龙脑(不得少于55.0％)。清香宣散，具有开窍醒神，清热散毒，明目退翳的功效，用于痔疮热病高热神昏，中风痰厥惊痫，暑湿蒙蔽清窍，喉痹耳聋，口疮齿肿，疮痈疳痔，目赤肿痛，翳膜遮睛。
玉竹为百合科植物玉竹根茎。具有养阴润燥，生津止渴的功效。主治燥咳，劳嗽，热病阴液耗伤之咽干口渴，内热消渴，阴虚外感，头昏眩晕，筋脉挛痛。
川芎为伞形科植物川芎的干燥根茎；5月采挖，除去泥沙，晒后烘干，再去须根。用时切片生用或酒炙功效为行气开郁、法风燥湿、活血止痛；主治风冷头痛眩晕、胁痛腹疼、寒痹筋挛、经闭、难产、产后瘀阻块痛、痈疽疮疡。用于月经不调、经闭痛经、瘕腹痛、胸胁刺痛、跌扑肿痛、头痛、风湿痹痛。
琥珀为古代松科植物的树脂埋藏地下经久凝结而成的碳氢化合物。从地层或煤层中挖出后，除去砂石、泥土等杂质。功能主治为：镇惊安神，散瘀止血，利水通淋。治惊风癫痫，惊悸失眠，血淋血尿，小便不通，妇女闭经，产后停瘀腹痛，痈疽疮毒，跌打创伤。
甘油即丙三醇，无色、无臭、味甜，外观呈澄明黏稠液态，能从空气中吸收潮气，也能吸收硫化氢、氰化氢和二氧化硫。难溶于苯、氯仿、四氯化碳、二硫化碳、石油醚和油类。丙三醇是甘油三酯分子的骨架成分。食用级甘油其中最优质一种，生物精化甘油，除含有丙三醇，还有酯类、葡萄糖等还原糖，属于多元醇类甘油；除具有保湿、保润功能外，还具有高活性、抗氧化、促醇化等特殊功效。每克甘油完全氧化可产生4千卡热量，经人体吸收后不会改变血糖和胰岛素水平。
优选地，各原料按重量份数计包含：棋楠树提取物60～80份，棋楠树叶提取物60～80份，棋楠精油20～30份，牛黄20～30份，麝香20～30份，薄荷提取物10～20份，冰片20～30份，玉竹40～60份，川芎40～60份，琥珀40～60份，甘油100～200份。
更优选地，各原料按重量计包含：棋楠树提取物70g，棋楠树叶提取物70g，棋楠精油25g，牛黄25g，麝香25g，薄荷提取物15g，冰片25g，玉竹50g，川芎50g，琥珀50g，甘油150g。
各原料均采用野生中草药材，多年生的采用五年或以上的药材。
本发明还提供了该用于心脑血管疾病的药剂的用途，该药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
本发明还提供了该外用雾化喷剂的制备方法，该方法为：按比例称量各药物，将固体原料研磨破碎成粉末，然后加水浸泡萃取，浓缩提纯，再与液体原料(甘油)，混合均匀超声后，制得外用雾化喷剂。
研磨破碎的粒度范围为50～60目。加水浸泡的时间为24小时或以上，加水量根据所需要的药剂用量调整。萃取采用超声法、渗漉法或回流法等。浓缩提纯采用加热蒸发水分，浓缩提纯前后液体的体积比为30：1。
下面结合实施例对本发明提供的用于心脑血管疾病的药剂及其制备方法与用途做更进一步描述。
实施例1
一种用于心脑血管疾病的药剂，该药剂的原料按重量计包含：棋楠树提取物70g，棋楠树叶提取物70g，棋楠精油25g，牛黄25g，麝香25g，薄荷提取物15g，冰片25g，玉竹50g，川芎50g，琥珀50g，甘油150g。
本实施例还提供了该用于心脑血管疾病的药剂的用途，该药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
本实施例还提供了该外用雾化喷剂的制备方法，该方法为：按比例称量各药物，将固体原料研磨破碎成粉末，研磨破碎的粒度范围为50～60目。然后加水浸泡萃取，加水浸泡的时间为24小时或以上，浓缩提纯。浓缩提纯前后液体的体积比为30：1，再与液体原料混合均匀超声后，制得外用雾化喷剂。
实施例2
一种用于心脑血管疾病的药剂，该药剂的原料按重量计包含：棋楠树提取物60g，棋楠树叶提取物60g，棋楠精油20g，牛黄20g，麝香20g，薄荷提取物10g，冰片20g，玉竹40g，川芎40g，琥珀40g，甘油100g。
本实施例还提供了该用于心脑血管疾病的药剂的用途，该药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
本实施例还提供了该外用雾化喷剂的制备方法，该方法为：按比例称量各药物，将固体原料研磨破碎成粉末，研磨破碎的粒度范围为50～60目。然后加水浸泡萃取，加水浸泡的时间为24小时或以上，浓缩提纯。浓缩提纯前后液体的体积比为30：1，再与液体原料混合均匀超声后，制得外用雾化喷剂。
实施例3
一种用于心脑血管疾病的药剂，该药剂的原料按重量计包含：棋楠树提取物80g，棋楠树叶提取物80g，棋楠精油30g，牛黄30g，麝香30g，薄荷提取物20g，冰片30g，玉竹60g，川芎60g，琥珀60g，甘油200g。
本实施例还提供了该用于心脑血管疾病的药剂的用途，该药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
本实施例还提供了该外用雾化喷剂的制备方法，该方法为：按比例称量各药物，将固体原料研磨破碎成粉末，研磨破碎的粒度范围为50～60目。然后加水浸泡萃取，加水浸泡的时间为24小时或以上，浓缩提纯。浓缩提纯前后液体的体积比为30：1，再与液体原料混合均匀超声后，制得外用雾化喷剂。
各实施例中采用的原料分别符合相应的国家标准。
采用各实施例制备的外用雾化喷剂进行临床试用，证明该药剂有明显效果，可以用于心悸心烦心慌、心动过速、心肌梗塞、心绞痛、心脑血管堵塞、二尖瓣反流三尖瓣反流或关闭不严等各类心脏疾病，以及中风偏瘫、口眼歪斜、四肢麻木、脑血管堵塞、脑溢血、脑梗塞等各类脑部疾病，或者用于急救心脑突发性病况。
本发明提供的用于心脑血管疾病的药剂及其制备方法与用途，经中医辨证，针对病证的病因病机，利用药物相辅相成的配伍原理，有目的地将诸药按君、臣、佐、使的组织结构合理配伍，使方中的药物及其配伍与病证的病机丝丝入扣，使药物配伍后的综合效用与所立治法高度统一。
尽管本发明的内容已经通过上述优选实施例作了详细介绍，但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后，对于本发明的多种修改和替代都将是显而易见的。因此，本发明的保护范围应由所附的权利要求来限定。
Claims (8)
1.一种用于心脑血管疾病的药剂，其特征在于，该药剂的原料包含：棋楠树提取物、棋楠树叶提取物、棋楠精油、牛黄、麝香、薄荷提取物、冰片、玉竹、川芎、琥珀、甘油。
2.如权利要求1所述的用于心脑血管疾病的药剂，其特征在于，所述的原料按重量份数计包含：棋楠树提取物60～80份，棋楠树叶提取物60～80份，棋楠精油20～30份，牛黄20～30份，麝香20～30份，薄荷提取物10～20份，冰片20～30份，玉竹40～60份，川芎40～60份，琥珀40～60份，甘油100～200份。
3.如权利要求2所述的用于心脑血管疾病的药剂，其特征在于，所述的原料按重量计包含：棋楠树提取物70g，棋楠树叶提取物70g，棋楠精油25g，牛黄25g，麝香25g，薄荷提取物15g，冰片25g，玉竹50g，川芎50g，琥珀50g，甘油150g。
4.一种如权利要求1～3中任意一项所述的用于心脑血管疾病的药剂的用途，其特征在于，所述的药剂用于制备心脑血管疾病患者吸入的外用雾化喷剂。
5.一种如权利要求4所述的外用雾化喷剂的制备方法，其特征在于，所述的方法为：按比例称量各药物，将固体原料研磨破碎成粉末，然后加水浸泡萃取，浓缩提纯，再与液体原料混合均匀超声后，制得外用雾化喷剂。
6.如权利要求5所述的外用雾化喷剂的制备方法，其特征在于，所述的研磨破碎的粒度范围为50～60目。
7.如权利要求5所述的外用雾化喷剂的制备方法，其特征在于，所述的加水浸泡的时间为24小时或以上。
8.如权利要求5所述的外用雾化喷剂的制备方法，其特征在于，所述的浓缩提纯前后液体的体积比为30：1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110955747.2A CN113476555A (zh) | 2021-08-19 | 2021-08-19 | 一种用于心脑血管疾病的药剂及其制备方法与用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110955747.2A CN113476555A (zh) | 2021-08-19 | 2021-08-19 | 一种用于心脑血管疾病的药剂及其制备方法与用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476555A true CN113476555A (zh) | 2021-10-08 |
Family
ID=77945781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110955747.2A Pending CN113476555A (zh) | 2021-08-19 | 2021-08-19 | 一种用于心脑血管疾病的药剂及其制备方法与用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476555A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344408A (zh) * | 2022-01-19 | 2022-04-15 | 国鼎山河(海南)医药集团有限责任公司 | 一种用于心脏疾病疏通心梗的组合物及其用途与制备方法 |
| CN114404526A (zh) * | 2022-02-07 | 2022-04-29 | 国鼎山河(海南)医药集团有限责任公司 | 一种用于脑梗和脑血管疾病的组合物及其用途与制备方法 |
| CN114958483A (zh) * | 2022-04-08 | 2022-08-30 | 四川农业大学 | 一种金丝楠精油提质增效方法以及包含金丝楠精油的复方精油 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1222359A (zh) * | 1997-06-13 | 1999-07-14 | 范东明 | 中药健脑帽药物组方及给药方式 |
-
2021
- 2021-08-19 CN CN202110955747.2A patent/CN113476555A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1222359A (zh) * | 1997-06-13 | 1999-07-14 | 范东明 | 中药健脑帽药物组方及给药方式 |
Non-Patent Citations (1)
| Title |
|---|
| 刘轶华,等: "血栓心脉宁治疗冠心病心绞痛105例分析", 《北方药学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344408A (zh) * | 2022-01-19 | 2022-04-15 | 国鼎山河(海南)医药集团有限责任公司 | 一种用于心脏疾病疏通心梗的组合物及其用途与制备方法 |
| CN114404526A (zh) * | 2022-02-07 | 2022-04-29 | 国鼎山河(海南)医药集团有限责任公司 | 一种用于脑梗和脑血管疾病的组合物及其用途与制备方法 |
| CN114958483A (zh) * | 2022-04-08 | 2022-08-30 | 四川农业大学 | 一种金丝楠精油提质增效方法以及包含金丝楠精油的复方精油 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113476555A (zh) | 一种用于心脑血管疾病的药剂及其制备方法与用途 | |
| CN103405373B (zh) | 一种天然乳液、制备方法及其应用 | |
| JP2005501851A (ja) | 毒素を除去するための組成物 | |
| CN107551031A (zh) | 一种缓解眼疲劳的中药组合物、包含其的眼贴及制备方法 | |
| KR20100022137A (ko) | 녹용을 포함하는 발효 한방 생약 추출물을 함유한 탈모방지용 화장품 샴푸 제조방법 및 샴푸 | |
| CN105342908A (zh) | 一种缓解皱纹的积雪草中药美容抗皱膏及其制备方法 | |
| CN111544543A (zh) | 一种具有清肺、解烟毒及解酒益肝功能的组合物 | |
| CN110141644A (zh) | 一种用于改善视力的药物组合物及其制备方法与用途 | |
| KR100873033B1 (ko) | 마사지팩용 화장료 조성물 | |
| CN106668274A (zh) | 具有美容、止痛止痒的外用中药保健制剂及其制备方法 | |
| CN108498390B (zh) | 一种治疗痤疮的藏本草提取物及其制备方法与应用 | |
| CN102139023A (zh) | 保健控烟型中草药吸品及制备方法 | |
| CN108403589A (zh) | 天然植物护肤霜 | |
| CN114983914A (zh) | 一种美白护肤品的制备方法 | |
| CN111150822A (zh) | 一种多功能本草原露雾化液 | |
| CN106580838A (zh) | 一种中药美白淡斑精华及其制备方法 | |
| CN113786459A (zh) | 一种用于心脑血管疾病的药物组合物及其制备方法与用途 | |
| KR101174046B1 (ko) | 한방 입욕제 및 그 제조방법 | |
| CN112891504A (zh) | 一种以生姜药渣为基材的四季护肤防疫生姜膏及制备方法 | |
| CN101284107B (zh) | 一种治癌药物及其制备方法 | |
| CN104547288A (zh) | 具有清除自由基祛红肿功效的外用中药组合物、制剂及其制备方法 | |
| CN107744569A (zh) | 一种具有养发、生发功效的精华液及其制备方法 | |
| CN106667852A (zh) | 一种中药祛痘霜及其制备方法 | |
| CN1050520C (zh) | 治疗慢性支气管炎和哮喘的中药 | |
| CN106668294A (zh) | 具有降血糖、降血脂和降血压功效的丹参叶复合保健茶及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |
|
| RJ01 | Rejection of invention patent application after publication |